130 related articles for article (PubMed ID: 23099805)
1. Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma.
Linnebank M; Moskau S; Kowoll A; Semmler A; Bangard C; Vogt-Schaden M; Egerer G; Schackert G; Reichmann H; Schmidt-Wolf IG; Pels H; Schlegel U
Br J Cancer; 2012 Nov; 107(11):1840-3. PubMed ID: 23099805
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.
Linnebank M; Moskau S; Jürgens A; Simon M; Semmler A; Orlopp K; Glasmacher A; Bangard C; Vogt-Schaden M; Urbach H; Schmidt-Wolf IG; Pels H; Schlegel U
Neuro Oncol; 2009 Feb; 11(1):2-8. PubMed ID: 18806228
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population.
Kurzwelly D; Knop S; Guenther M; Loeffler J; Korfel A; Thiel E; Hebart H; Simon M; Weller M; Linnebank M; Herrlinger U
J Neurooncol; 2010 Nov; 100(2):187-92. PubMed ID: 20237949
[TBL] [Abstract][Full Text] [Related]
4. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism.
Linnebank M; Pels H; Kleczar N; Farmand S; Fliessbach K; Urbach H; Orlopp K; Klockgether T; Schmidt-Wolf IG; Schlegel U
Neurology; 2005 Mar; 64(5):912-3. PubMed ID: 15753437
[TBL] [Abstract][Full Text] [Related]
5. Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate.
Becker A; Vezmar S; Linnebank M; Pels H; Bode U; Schlegel U; Jaehde U
Int J Clin Pharmacol Ther; 2007 Sep; 45(9):504-15. PubMed ID: 17907593
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
Cobert J; Hochberg E; Woldenberg N; Hochberg F
J Neurooncol; 2010 Jul; 98(3):385-93. PubMed ID: 20020180
[TBL] [Abstract][Full Text] [Related]
8. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
[TBL] [Abstract][Full Text] [Related]
9. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
10. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
[TBL] [Abstract][Full Text] [Related]
12. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
13. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
14. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
15. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy.
Steinbeck JA; Stuplich M; Blasius E; Pels H; Glas M; Schlegel U; Herrlinger U
J Clin Neurosci; 2011 Nov; 18(11):1554-5. PubMed ID: 21868233
[TBL] [Abstract][Full Text] [Related]
16. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
Hayano A; Takashima Y; Yamanaka R
Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma: a clinicopathological study of 28 cases.
Pels H; Deckert-Schlüter M; Glasmacher A; Kleinschmidt R; Oehring R; Fischer HP; Bode U; Schlegel U
Hematol Oncol; 2000 Mar; 18(1):21-32. PubMed ID: 10797527
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
[TBL] [Abstract][Full Text] [Related]
19. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study.
Schlegel U; Pels H; Glasmacher A; Kleinschmidt R; Schmidt-Wolf I; Helmstaedter C; Fliessbach K; Deckert M; Van Roost D; Fimmers R; Bode U; Klockgether T
J Neurol Neurosurg Psychiatry; 2001 Jul; 71(1):118-22. PubMed ID: 11413277
[TBL] [Abstract][Full Text] [Related]
20. A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
Taoka K; Okoshi Y; Sakamoto N; Takano S; Matsumura A; Hasegawa Y; Chiba S
Int J Hematol; 2010 Nov; 92(4):617-23. PubMed ID: 20967518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
